Compugen Reports Results Further Confirming CGEN-15049 as 'Promising' Target Candidate for Cancer Immunotherapy
October 01, 2014 at 07:10 AM EDT
Compugen Ltd. (NASDAQ: CGEN) today disclosed results from recent studies further confirming CGEN-15049 as a promising target candidate ...